Clinical Trials Logo
NCT number NCT01453088
Study type Interventional
Source Hackensack University Medical Center
Contact Michele Donato, MD
Phone 201-996-5900
Email MDonato@humed.com
Status Recruiting
Phase Phase 2
Start date June 2010
Completion date December 2015
View Details

Clinical Trial Summary

In this study the investigators are comparing this standard regimen to the newly established regimen of melphalan and bortezomib.


Clinical Trial Description

In this study the investigators are comparing this standard regimen to the newly established regimen of melphalan and bortezomib.

Conditioning Regimens:

Treatment arm A Melphalan is administered at a dose of 200mg/m2 by rapid intravenous infusion via a central or peripheral vein over 30 minutes to one hour.

Melphalan will be given as a single dose (not split over 2 or more days) and given on day-1.

Dosing will be based on body surface area calculated using actual body weight

Stem cell infusion:

Stem cell infusion will occur on day 0 and will be at least 20 hours after the infusion of melphalan. The infusion of peripheral blood stem cells will be done in accordance with the Blood and Marrow Transplant program standard operating procedures.

Filgrastim will be administered at a dose of 5 mcg/kg (rounded to vial size) every other day starting on day+3 then daily starting on day 9 until engraftment (at least).

Treatment arm B

Bortezomib:

Bortezomib is administered by rapid I.V. push (over 3-5 seconds) via a central or peripheral vein into a flowing saline line. Bortezomib will be administered any time on day -4 and at least 20 hrs after the start of the melphalan infusion on day -1.

Dosing will be based on actual body weight. Dexamethasone is administered at a dose of 20 mg IV prior to each bortezomib infusion.

Melphalan:

Melphalan is administered at a dose of 200mg/m2 by rapid intravenous infusion via a central or peripheral vein over 30 minutes to one hour.

Melphalan will be given as a single dose (not split over 2 or more days) and given of day-2.

Dosing will be based body surface area calculated using actual body weight

Stem cell infusion:

Stem cell infusion will occur on day 0 and will be at least 18 hours after the infusion of the bortezomib. The infusion of peripheral blood stem cells will be done in accordance with the Blood and Marrow Transplant program standard operating procedures.

Filgrastim will be administered at a dose of 5 mcg/kg (rounded to vial size) every other day starting on day+3 then daily starting on day 9 until engraftment (at least).

Post-transplant Supportive Care will be administered in accordance to the Blood and Marrow Transplant program standard operating procedures.


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Clinical Trial Details
See also
Status Clinical Trial Phase
 Not yet recruiting NCT02843074 - Elotuzumab, Lenalidomide and Dexamethasone (ERd) in the Induction, Consolidation and Maintenance Treatment of Transplant-Eligible, Newly Diagnosed Multiple Myeloma Patients Phase 2
 Not yet recruiting NCT02811978 - Study of Subcutaneous and Intravenous Velcade in Combination With Dexamethasone in Chinese Subjects With Relapsed and Refractory Multiple Myeloma Phase 3
 Not yet recruiting NCT02802163 - Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,Panobinostat Phase 1/Phase 2
 Not yet recruiting NCT02780609 - Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma Phase 1/Phase 2
 Not yet recruiting NCT02786485 - Study of Matched Unrelated Donor T Cell Infusion for Adults With Recurrent or Minimal Residual Disease Hematologic Malignancies After Allogeneic Transplant Phase 1
 Recruiting NCT02499081 - UARK 2014-14: Phase II Prospective Evaluation of Bone Remodeling During Ixazomib Treatment Phase 2
 Recruiting NCT02541383 - A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma Phase 3
 Recruiting NCT02566265 - Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing IN Gammopathy Patients Phase 2
 Recruiting NCT02546167 - CART-BCMA Cells for Multiple Myeloma Phase 0
 Recruiting NCT02506959 - Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Myeloma Phase 2
 Recruiting NCT02384083 - Filanesib (ARRY-520) in Combination With Pomalidomide and Dexamethasone for Relapsed/Refractory (R/R) Multiple Myeloma (MM) Patients Phase 1/Phase 2
 Recruiting NCT02507479 - Thiotepa-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies Phase 2
 Recruiting NCT02412878 - A Study in Subjects With Relapsed and Refractory Multiple Myeloma Receiving Carfilzomib in Combination With Dexamethasone, Comparing Once-weekly Versus Twice-weekly Carfilzomib Dosing (ARROW) Phase 3
 Recruiting NCT02575144 - GEM-CLARIDEX: Ld vs BiRd Phase 3
 Recruiting NCT02169791 - Nonmyeloablative Haploidentical Transplant Followed by MLN9708 Phase 2
 Recruiting NCT02206425 - Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients Phase 1/Phase 2
 Recruiting NCT02160951 - Dose Escalation Study of LGH447 in Japanese Patients With Relapsed and/or Refractory Hematologic Malignancies Phase 1
 Recruiting NCT02186834 - Selinexor (KPT-330) and Pegylated Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma Phase 1/Phase 2
 Active, not recruiting NCT02223598 - A Phase 1 Study Evaluating CB-5083 in Patients With Relapsed/Refractory Multiple Myeloma Phase 1
 Recruiting NCT01947140 - Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies Phase 1/Phase 2